Werewolf Therapeutics
HOWL
51 hedge funds and large institutions have $9.34M invested in Werewolf Therapeutics in 2025 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 14 increasing their positions, 17 reducing their positions, and 15 closing their positions.
15.8% less ownership
Funds ownership: 46.16% → 30.36% (-16%)
18% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 17
18% less funds holding
Funds holding: 62 → 51 (-11)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
53% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 15
78% less capital invested
Capital invested by funds: $41.6M → $9.34M (-$32.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$797K |
| 2 |
Renaissance Technologies
New York
|
+$270K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$58.3K |
| 4 |
Morgan Stanley
New York
|
+$32.5K |
| 5 |
RIA
Regal Investment Advisors
Kentwood,
Michigan
|
+$30.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$1.33M |
| 2 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$1.23M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$790K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$304K |
| 5 |
Jane Street
New York
|
-$135K |
HOWL Hedge Fund Activity: Q4 2025 in Review
51 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Werewolf Therapeutics (HOWL) for Q4 2025, worth a combined $9.34M — down 78% from $41.6M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of HOWL and 7 opened new positions — a net loss of 8 holders — while 17 trimmed existing stakes and 14 added.
The largest buyer was Lynx1 Capital Management, opening a new position worth an estimated $797K. The largest seller was Bank of America, cutting an estimated $1.33M.
- 51 institutional investors held Werewolf Therapeutics (HOWL) as of Q4 2025, down from 62 in Q3 2025.
- Funds reported $9.34M of Werewolf Therapeutics stock for Q4 2025, down 78% quarter-over-quarter.
- 7 funds opened new Werewolf Therapeutics positions in Q4 2025 and 15 closed out, a net change of -8 holders.
- The largest Werewolf Therapeutics buyer in Q4 2025 was Lynx1 Capital Management, an estimated $797K added.
- The largest Werewolf Therapeutics seller in Q4 2025 was Bank of America, an estimated $1.33M sold.
Based on aggregated 13F filings for Q4 2025.